Earnings ·
DBV reports $64.5M Q3 loss, submits BLA for VIASKIN Peanut Patch in children aged 4-7
DBVTFDBV Technologies S.A.
DBV Technologies reported a net loss of $64.5 million ($0.14 per share) for the third quarter ended September 30, 2026, compared to a $33.2 million loss in the prior year period. The company submitted its Biologics License Application (BLA) to the U.S. FDA for VIASKIN Peanut Patch in children aged 4 through 7 years and requested Priority Review. R&D expenses rose to $47.0 million, while sales and marketing costs increased to $5.3 million as the firm scales commercial readiness. DBV holds $165.7 million in cash, funding operations into Q3 2027, though substantial doubt exists regarding its ability to continue as a going concern within twelve months. The company also completed a $50 million equity sale under its ATM program.